Moxaverine

Moxaverine
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
IUPAC name
  • 1-Benzyl-3-ethyl-6,7-dimethoxyisoquinoline
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.031.003 Edit this at Wikidata
Chemical and physical data
FormulaC20H21NO2
Molar mass307.393 g·mol−1
3D model (JSmol)
SMILES
  • CCC1=NC(=C2C=C(C(=CC2=C1)OC)OC)CC3=CC=CC=C3
InChI
  • InChI=1S/C20H21NO2/c1-4-16-11-15-12-19(22-2)20(23-3)13-17(15)18(21-16)10-14-8-6-5-7-9-14/h5-9,11-13H,4,10H2,1-3H3 ☒N
  • Key:MYCMTMIGRXJNSO-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Moxaverine has been used in therapy based on the direct vasodilatory effect of the drug, a phosphodiesterase inhibitor,[1] and on its influence on the rheological properties of red blood cells.[2]

Moxaverine hydrochloride (Kollateral forte®, Ursapharm. Saarbrücken, Germany) has been shown to increase ocular blood flow in patients with age-related macular degeneration, primary open angle glaucoma, and to increase choroidal and retrobulbar blood flow in elderly patients with eye diseases associated with hypo-perfusion.[3] The ocular efficacy of moxaverine has been explored in the clinic.[4]

References

  1. ↑ Mannhold R (December 1988). "Inhibition of calmodulin dependent c-AMP-phosphodiesterase by moxaverine and papaverine". Arzneimittel-Forschung. 38 (12): 1806–8. PMID 2854468.
  2. ↑ Schmid-Schönbein H, Schröder S, Grebe R, Artmann G, Eschweiler H, Teitel P (May 1988). "Influence of moxaverine hydrochloride on membrane curvature and microsieve filterability of red cells after exposure to hyperosmolarity and lactacidosis". Arzneimittel-Forschung. 38 (5): 710–6. PMID 3415714.
  3. ↑ Pemp B, Garhofer G, Lasta M, Schmidl D, Wolzt M, Schmetterer L (March 2012). "The effects of moxaverine on ocular blood flow in patients with age-related macular degeneration or primary open angle glaucoma and in healthy control subjects". Acta Ophthalmologica. 90 (2): 139–45. doi:10.1111/j.1755-3768.2010.01878.x. PMID 20456253. S2CID 3269602.
  4. ↑ Clinical trial number NCT01629680 for "A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects" at ClinicalTrials.gov
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.